Nuvalent: Strategic Progress and Pipeline Advancements Solidify Buy Rating
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Nuvalent (NUVL – Research Report) and keeping the price target at ...
Nuvalent, Inc. Q3 Loss Increases
Nuvalent, Inc. (NUVL) reported Loss for its third quarter that increased from the same period last year The company's bottom line ...
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline ...